Skip to search formSkip to main contentSkip to account menu

netazepide

Known as: 1-((3R)-1-(3,3-Dimethyl-2-Oxobutyl)-2-Oxo-5-(Pyridin-2-yl)-2,3-Dihydro-1H-1,4-Benzodiazepin-3-yl)-3-(3-(Methylamino)Phenyl)Urea, Sograzepide 
An orally active, benzodiazepine type, selective cholecystokinin B receptor (CCKBR; CCK2R; gastrin receptor) antagonist with potential gastric acid… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

YF 476

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment
Objective Netazepide (YF476) is a recently developed, orally active gastrin receptor antagonist that, in short trials in patients… 
2016
2016
Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis
2016
2016
Clinical pharmacology of netazepide, a gastrin/CCK-2 receptor antagonist
2015
2015
Sa1824 Identification of Potential Biomarkers of Netazepide (YF476) Treatment of Type I Gastric Neuroendocrine Tumours
2014
2014
Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Embodiments that provide are based in part on evidence of our role in the role of gastrin in regulating the aging digestive tract… 
2014
2014
Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
The provided embodiments are based in some aspects on the demonstration herein of a role for gastrin in regulating the aging gut… 
2014
2014
Skeletal effects of the gastrin receptor antagonist netazepide in H+/K+ATPase beta-subunit deficient mice
2013
2013
Sa2016 Netazepide, a Gastrin/CCK-2 Receptor Antagonist, Causes Regression of Type 1 Gastric Neuroendocrine Tumors and Reduces Expression of Chromogranin a and Histidine Decarboxylase Genes in Chronic…
2012
2012
Commentary: netazepide for gastric acid suppression – another kid on the block?
We agree with Drs Yu and Wong that magnetic resonance imaging (MRI)-derived proton-density-fat-fraction (PDFF) provides an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)